Latest Upfront Chromatography A/S Stories
Therapure Biopharma Inc.
PARSIPPANY, N.J., May 4 /PRNewswire/ -- DSM Biologics, a business unit of DSM Pharmaceutical products, today announced it has reached an agreement for the acquisition of the assets and associated business of the Rhobust(TM) technology from Upfront Chromatography A/S (Denmark) for pharmaceutical and other applications. As a result of the acquisition, DSM Biologics will gain all rights for the commercialization of the Rhobust(TM) technology in various fields, including the pharma industry.
- A volcanic mudflow.